| Michael Paul Emswiler, MD | |
|
7101 Jahnke Rd, :emergency Medicine, Richmond, VA 23225-4017 | |
| (804) 320-3911 | |
| Not Available |
| Full Name | Michael Paul Emswiler |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 13 Years |
| Location | 7101 Jahnke Rd, Richmond, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679864821 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 0101256269 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cjw Medical Center | Richmond, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emergency Coverage Corp | 3072412592 | 364 |
News Archive
It is important to understand the vaccine effectiveness (VE) to determine how much protection it offers to the general population. Unfortunately, only a few studies are available that have determined the effect of the COVID-19 vaccine among the residents of LTCFs.
UK researchers in collaboration with patients and clinicians have developed a new diary to be used to record lower urinary tract symptoms.
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today that it has filed an application with China's Food and Drug Administration to conduct a Phase 2 clinical trial in fibrolamellar carcinoma (FLC) patients in China for its proprietary drug candidate, ENMD-2076.
People who suffer with chronic musculoskeletal pain face a daily struggle with their sense of self and find it difficult to prove the legitimacy of their condition.
› Verified 3 days ago
| Entity Name | Emergency Coverage Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427005008 PECOS PAC ID: 3072412592 Enrollment ID: O20050418000414 |
News Archive
It is important to understand the vaccine effectiveness (VE) to determine how much protection it offers to the general population. Unfortunately, only a few studies are available that have determined the effect of the COVID-19 vaccine among the residents of LTCFs.
UK researchers in collaboration with patients and clinicians have developed a new diary to be used to record lower urinary tract symptoms.
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today that it has filed an application with China's Food and Drug Administration to conduct a Phase 2 clinical trial in fibrolamellar carcinoma (FLC) patients in China for its proprietary drug candidate, ENMD-2076.
People who suffer with chronic musculoskeletal pain face a daily struggle with their sense of self and find it difficult to prove the legitimacy of their condition.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Paul Emswiler, MD Po Box 91734, Richmond, VA 23291-1734 Ph: (804) 358-6100 | Michael Paul Emswiler, MD 7101 Jahnke Rd, :emergency Medicine, Richmond, VA 23225-4017 Ph: (804) 320-3911 |
News Archive
It is important to understand the vaccine effectiveness (VE) to determine how much protection it offers to the general population. Unfortunately, only a few studies are available that have determined the effect of the COVID-19 vaccine among the residents of LTCFs.
UK researchers in collaboration with patients and clinicians have developed a new diary to be used to record lower urinary tract symptoms.
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today that it has filed an application with China's Food and Drug Administration to conduct a Phase 2 clinical trial in fibrolamellar carcinoma (FLC) patients in China for its proprietary drug candidate, ENMD-2076.
People who suffer with chronic musculoskeletal pain face a daily struggle with their sense of self and find it difficult to prove the legitimacy of their condition.
› Verified 3 days ago
Robert Weisberger, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 5801 Bremo Rd, Virginia Emergency Associates Inc, Richmond, VA 23226 Phone: 804-287-7066 Fax: 804-673-9531 | |
Dr. Michael Ferebee, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1602 Skipwith Rd, Richmond, VA 23229 Phone: 757-329-3754 | |
James R Shefferly, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 5801 Bremo Rd, Virginia Emergency Associates Inc, Richmond, VA 23226 Phone: 804-287-7066 Fax: 804-673-9531 | |
Jeffry A Zimmerman, P.A. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5801 Bremo Rd, St Francis Emergency Department, Richmond, VA 23226 Phone: 804-287-7066 Fax: 804-673-9531 | |
Shawn M Borich, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3200 Rockbridge St Ste 103, Richmond, VA 23230 Phone: 804-386-0200 | |
Tamera Barnes, MD, FACEP Emergency Medicine Medicare: Medicare Enrolled Practice Location: 7101 Jahnke Rd, Richmond, VA 23225 Phone: 804-330-2000 | |
Dr. Kevin James Noreika, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1401 Johnston Willis Dr, Richmond, VA 23235 Phone: 804-330-2277 |